2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor
Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.Peer-Reviewed Original ResearchConceptsUterine carcinosarcomaCS cell linesSignature 3Cell linesPolymerase inhibitorsOverall animal survivalFresh tumor samplesPoly (ADP-ribose) polymerase (PARP) inhibitorsXenograft tumor growthG2/M phaseAggressive malignancyCS patientsPrimary tumorCell cycle arrestPrimary cell linesPoor survivalClinical studiesPreclinical sensitivityCarcinosarcomaTumor growthAnimal survivalOlaparib activityTumor samplesOlaparibAntitumor activity
2007
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma
Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.Peer-Reviewed Original ResearchConceptsDeep myometrial invasionCA125 elevationExtrauterine diseasePrognostic factorsUterine carcinosarcomaPreoperative CA125CA125 levelsCA125 measurementMyometrial invasionPoor survivalExact testCox proportional hazards modelClinicopathologic prognostic factorsEstrogen receptor positivityIndependent prognostic factorManagement of patientsUnivariate survival analysisUseful serum markerPearson's chi-square testProportional hazards modelFisher's exact testChi-square testSerous histologyConsecutive patientsReceptor positivity